WST
West Pharmaceutical Services Inc.
$318.47
+$2.05(+0.65%)
53
Overall
50
Value
60
Tech
50
Quality
Market Cap
$19.36B
Volume
221.65K
52W Range
$206.10 - $330.88
Target Price
$350.62
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.5B | $1.6B | $1.7B | $1.8B | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B | ||
| Total Revenue | $1.5B | $1.6B | $1.7B | $1.8B | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $1.0B | $1.1B | $1.2B | $1.2B | $1.4B | $1.7B | $1.8B | $1.8B | $1.9B | $2.0B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $501.1M | $512.9M | $545.4M | $605.7M | $767.8M | $1.2B | $1.1B | $1.1B | $998.5M | $1.1B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $304.3M | $287.1M | $305.1M | $309.1M | $360.9M | $407.7M | $375.4M | $421.8M | $407.6M | $467.9M | ||
| Research & Development | $36.8M | $39.1M | $40.3M | $38.9M | $46.9M | $52.8M | $58.5M | $68.4M | $69.1M | $74.3M | ||
| Research Expense | $36.8M | $39.1M | $40.3M | $38.9M | $46.9M | $52.8M | $58.5M | $68.4M | $69.1M | $74.3M | ||
| Selling, General & Administrative | $239.8M | $246.0M | $262.9M | $272.7M | $302.0M | $362.8M | $316.9M | $353.4M | $338.5M | $393.6M | ||
| Selling & Marketing Expenses | $239.8M | $246.0M | $262.9M | $272.7M | $302.0M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-11.7M | $-13.3M | $-14.5M | $-17.0M | $-17.4M | $362.8M | $316.9M | $353.4M | $338.5M | $393.6M | ||
| Salaries & Wages | $27.7M | $2.0M | $1.9M | $-2.5M | $12.0M | $-7.9M | -- | $23.3M | $18.7M | $23.8M | ||
| Depreciation & Amortization | $-90.7M | $-96.7M | $-104.4M | $-103.4M | $-109.1M | $122.3M | $120.6M | $137.3M | $155.4M | -- | ||
| Depreciation & Amortization | $-90.7M | $-96.7M | $-104.4M | $-103.4M | $-109.1M | $122.3M | -- | -- | -- | -- | ||
| Amortization | $-2.6M | $-2.4M | $-2.7M | $-3.4M | $-4.4M | $109.9M | $107.3M | $108.5M | $3.6M | $2.8M | ||
| Other Operating Expenses | $-1.0M | $-400.0K | $-4.8M | $-12.9M | $-12.8M | $-16.3M | $-600.0K | $1.3M | $900.0K | $1.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $196.8M | $225.8M | $240.3M | $296.6M | $406.9M | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M | ||
| EBITDA | $296.8M | $336.1M | $361.1M | $412.6M | $518.6M | $879.4M | $829.1M | $862.0M | $758.6M | $787.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $8.1M | $7.8M | $8.4M | $8.5M | $8.2M | $8.2M | $7.9M | $9.0M | $3.0M | $500.0K | ||
| Intinc | -- | -- | -- | $-4.8M | $-5.6M | -- | -- | -- | $19.6M | -- | ||
| Net Non-Operating Interest Income/Expense | $-7.0M | $-6.5M | $-6.3M | $-4.7M | $-6.8M | $-8.2M | $2.8M | $-5.8M | $-3.0M | $-500.0K | ||
| Gain on Sale of Securities | -- | $-11.1M | -- | -- | $-2.5M | $1.0M | $5.1M | $28.0M | $19.6M | $17.5M | ||
| Other Income/Expense | $-8.2M | $-12.3M | $-14.3M | $-8.8M | $-18.6M | $-24.9M | $-78.1M | $-48.7M | $-33.3M | $-30.9M | ||
| Other Special Charges | $2.3M | $3.1M | $6.7M | $-100.0K | $1.2M | $3.8M | $-51.3M | $3.0M | $-1.0M | $-1.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-26.4M | -- | $-9.1M | $-4.9M | $-4.6M | $2.2M | $23.8M | $-2.8M | $-2.5M | $24.6M | ||
| Special Income Charges | $43.7M | -- | $11.3M | $5.2M | $4.6M | $-2.2M | $-6.0M | $-6.8M | $2.5M | $-24.6M | ||
| Impairment of Capital Assets | $-17.3M | -- | $-2.2M | $-300.0K | -- | -- | $6.2M | $9.6M | $7.3M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $206.1M | $239.4M | $256.7M | $309.2M | $409.5M | $757.1M | $708.5M | $724.7M | $603.2M | $615.8M | ||
| Pre-Tax Income | $198.0M | $231.6M | $248.3M | $300.7M | $418.7M | $748.9M | $679.9M | $698.0M | $585.5M | $600.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $54.4M | $80.9M | $41.4M | $59.0M | $72.5M | $107.2M | $114.7M | $122.3M | $107.5M | $121.6M | ||
| NET INCOME | ||||||||||||
| Net Income | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M | ||
| Net Income (Continuing Operations) | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M | ||
| Net Income (Discontinued Operations) | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M | ||
| Net Income (Common Stockholders) | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M | ||
| Normalized Income | $82.7M | $152.9M | $186.4M | $227.6M | $317.3M | -- | -- | -- | -- | $628.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $1.3B | $1.4B | $1.5B | $1.5B | $1.7B | $2.1B | $2.1B | $2.2B | $2.3B | $2.4B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $73.3M | $73.9M | $73.9M | $74.0M | $73.9M | $74.4M | $74.4M | $74.3M | $73.0M | $72.3M | ||
| Average Shares Outstanding (Diluted) | $75.0M | $75.8M | $75.4M | $75.4M | $75.8M | $76.3M | $75.8M | $75.3M | $73.7M | $72.7M | ||
| Shares Outstanding | $73.3M | $74.0M | $74.2M | $73.8M | $74.1M | $74.3M | $74.1M | $73.3M | $72.3M | $72.0M | ||
| Basic EPS | $1.96 | $2.04 | $2.8 | $3.27 | $4.68 | $8.89 | $7.87 | $7.98 | $6.75 | $6.83 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $8.89 | $7.87 | $7.98 | $6.75 | $6.83 | ||
| Diluted EPS | $1.91 | $1.99 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | ||
| Dividend Per Share | $0.49 | $0.53 | $0.57 | $0.61 | $0.65 | $0.69 | $0.73 | $0.77 | $0.82 | $0.86 | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | $8.2M | $9.2M | $7.6M | $8.9M | $17.4M | $20.1M | $20.7M | $17.7M | $14.7M | $14.4M | ||
| Earnings From Equity Interest Net Of Tax | $8.2M | $9.2M | $7.6M | $8.9M | $17.4M | $20.1M | $20.7M | $17.7M | $14.7M | $14.4M | ||
| Gain On Sale Of P P E | -- | -- | $1.1M | $1.9M | -- | -- | -- | $-11.6M | -- | -- | ||
| Other Gand A | $-11.7M | $-13.3M | $-14.5M | $-17.0M | $-17.4M | $362.8M | $316.9M | $353.4M | $338.5M | $393.6M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $-800.0K | $-7.7M | $4.6M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-11.7M | $-13.3M | $-14.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $239.8M | $246.0M | $262.9M | $272.7M | $302.0M | -- | -- | -- | -- | -- | ||
| Restruct | $-26.4M | -- | $-9.1M | $-4.9M | $-4.6M | $2.2M | $23.8M | $-2.8M | $-2.5M | $24.6M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | WST | $318.47 | +0.6% | 221.65K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get West Pharmaceutical Services Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW